Amphion Innovations plc

Amphion to Present in London

London and New York, 17 September 2015 - Amphion Innovations plc (AIM: AMP) (“Amphion” or the “Company”), the developer of medical, life science and technology businesses, announces today that the Company’s CEO, Richard Morgan, will present at Proactive Investors’ One2One Forum on 24 September 2015 at 6pm at the Chesterfield Mayfair Hotel in London.  Graham Lumdsen, CEO of Amphion Partner Company, Motif Bio plc (AIM: MTFB) will also be presenting. 

For more information or to register to attend, please contact Thomas Coleman at Proactive Investors or visit:


For further information please contact

Amphion Innovations
Charlie Morgan
+1 212 210 6224

Yellow Jersey PR
Charles Goodwin / Dominic Barretto
+44 (0)7747 788 221

Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Duncan Monteith (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500

Northland Capital Partners Limited (Joint Corporate Broker)
Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Mark Treharne (Corporate Broking)
+44 (0)20 7382 1100

Plumtree Capital Limited (Financial Adviser)
Stephen Austin
+44 (0)20 7183 2493
+646 568 7502

About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.